Urology and Pelvic health market Archives

Rising incidence of kidney stones, bladder cancer, and other bladder disorders; the shift to minimally invasive procedures; technological developments in urology and pelvic health devices; and the investments made by top market players in research and development for new product development are some of the main factors propelling the market growth. Urology and pelvic health is a medical and surgical specialty involving disorders of the genitourinary tract and the adrenal glands. Urologists addresses the conditions affecting kidneys, ureters, bladder, and urethra in both men and women. The urology and pelvic health market is segmented on the basis of product, application, and end-user. Get Free Sample of the Report : https://meditechinsights.com/urology-and-pelvic-health-market/request-sample/ Technological Innovations in Urology And Pelvic Health Market to Drive its the Global Market Demand Continuous improvements in the urology and pelvic health markets have enabled the development of efficient goods with improved characteristics such as minimally invasive procedures, fast recovery, and infection reduction. Major manufacturers have lately introduced technologically improved goods to broaden their geographic reach and boost their position in the global urology and pelvic health market. Some of the technical advances are highlighted below: In November 2022, Teleflex launched its UroLift System in India, a minimally invasive approach for the treatment of benign prostatic hyperplasia (BPH) or prostate enlargement providing a rapid symptomatic relief for men allowing quick recovery. In November 2022, Coloplast launched SpeediCath Flex Set, a new catheter in the US market, featuring a triple action coating technology specifically designed to reduce the risk of Urinary Tract Infections (UTIs) and urethral damage. In September 2022, Olympus Corporation launched its VISERA ELITE III Surgical Visualization Platform that support imaging functions and minimally invasive therapies, to address the needs of healthcare professionals for endoscopic procedures including urology. In May 2022, Auris Health, Inc., a subsidiary of Ethicon, Inc., received the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MONARCH Platform for endourological procedures. In November 2021, The Flume Catheter Company Ltd. (TFCC) received the US Food and Drug Administration (FDA) clearance for its FLUME catheter, a new indwelling urinary catheter designed to address the drawbacks of traditional Foley catheter design. Leading market players invest in the urology and pelvic health market to boost product development. Market companies in the urology and pelvic health sectors are continually focused on investments and collaborations to accelerate new product development. These expenditures are aimed at increasing firms' technological capabilities in order to produce new products that will benefit both the company and its customers. Such developments often provide all producers a competitive advantage. Some of the recent developments are listed below- In December 2022, Minze Health, a Belgium-based digital health company raised US$ 4.2 million (€ 3.9 million) from White Fund, Capricorn Partners, and PMV; to further scale its digital health solutions aimed at treating urinary tract problems. In April 2022, Cosm, a Canada-based start-up raised US$ 3.8 million (CAD 4.7 million) to advance its digital gynecology platform, a software-enabled medical device platform aimed at treating pelvic floor disorders. In September 2021, Boston Scientific Corporation acquired the global surgical business of Lumenis LTD. This acquisition was aimed at integrating the Lumenis laser portfolio with Boston Scientific’s kidney stone management and benign prostatic hyperplasia offerings. In April 2021, Renovia, a digital therapeutics company raised US$ 17 million Series C-1 financing round backed by Perceptive Life Sciences, Longwood Fund, Ascension Ventures and OSF Ventures, and Parian Global Management; to support the clinical development and launch of leva digital therapeutic used for the treatment of urinary incontinence and other pelvic floor disorders. North America is expected to hold a major share in the Urology And Pelvic Health Market From a geographical perspective, North America holds a major market share of the urology and pelvic health market. This can be mainly attributed to the investments by hospitals to procure advanced urology and pelvic health devices, favorable reimbursement policies, and developed healthcare infrastructure. For instance, in December 2021, Vizient Inc. (a US-based member-owned healthcare company which includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers) and Ambu Inc. (manufacturer of single-use endoscopes) entered in a contract to offer Vizient members a pre-negotiated pricing for Ambu’s single-use products in bronchoscopy, urology, ENT and GI. However, the Asia Pacific is expected to ascend at the fastest CAGR over the forecast period on account of the large customer base and growing health concerns in key markets such as Japan, China & India; rising disposable income; improving healthcare infrastructure; and rapidly growing target patient population. Competitive Landscape Analysis: Urology And Pelvic Health Market The global urology and pelvic health market is marked by the presence of key market players such as follows:- Boston Scientific Corporation (US) Medtronic plc (Ireland) Coloplast (Denmark) B. Braun Melsungen AG (Germany) ConvaTec Group (UK) Hollister Incorporated (US) Teleflex Inc. (US) Stryker Corporation (US) Ethicon (US) COVID-19 negatively impacted the Global Urology And Pelvic Health Market The COVID-19 pandemic had a negative impact on some of the urology and pelvic health market players. Sales of these products fell significantly as a result of cancellations of non-urgent urological procedures. Some of the manufacturers reported significant revenue losses as a result of the fall in demand. However, post-pandemic, the demand is being supported by relaxation of restrictions, resumption of hospital services, and the steady increase in patient traffic. Company revenues have increased significantly since the pandemic. Some of the barriers to market expansion include the high cost of sophisticated urology and pelvic health technologies, an unfavorable reimbursement environment, and a shortage of qualified technicians. Regardless of these problems, the urology and pelvic health market is predicted to rise steadily as industry participants focus on developing new products with better capabilities. Substantial breakthroughs in minimally invasive approaches, reduction in subsequent infections, and increasing frequency of kidney disorders, among other factors, are projected to boost the worldwide urology and pelvic health market development. Get Detailed Insights on the Urology And Pelvic Health Market @ https://meditechinsights.com/urology-and-pelvic-health-market/

Tag: Urology and Pelvic health market

Global Urology and Pelvic health market is expected to increase at a pace of 8% during the next five years

The Global Single-use Bioreactors Market is set to surge at a high CAGR of 20% by 2029.

Global Biologics CDMO Market is set to soar at substantial CAGR of 14–16% in the next five years.

Oncology Information System Market Projected to Witness High Growth of 8% from 2024 to 2029

The Transplantation Market Expected to Grow at a 9-10% CAGR by 2029, Fueled by Advancements in Transplant Technologies

The Bioburden Testing Market Maintains Strong CAGR with Growing Demand for Sterilization Assurance

The Fluoroscopy Equipment Market is Poised to grow at a CAGR of 5–7%.

The Bionic Contact Lenses Market is poised to grow at a high CAGR of 11-13%

Global Biosimulation Market Envisions a Promising Future to Have a High 15-20% Growth by 2028

Global Intraocular Lens (IOLs) Market Expecting a Decent 5-6% CAGR in the Next 5 Years

The Cardiology Information System (CIS) Market is projected to grow at a healthy CAGR of 8-10% over the next few years.